Yazar "Erdem, Mehmet" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Could ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding?
    (2024) KIRAN, TUGBA RAIKA; Doğan, Ümran Karabulut; Otlu, Önder; yildirim, engin; Erdem, Mehmet; İnceoğlu, Feyza
    Aim: Abnormal uterine bleeding (AUB) is a health problem characterized by various symptoms such as heavy and prolonged menstrual bleeding, affecting approximately 30% of female patients both physiologically and psychologically. The objective of this study was to assess serum Elabela (ELA) concentrations in women aged 18 and above diagnosed with functional AUB, and to compare these concentrations with those of healthy women. Material and Method: This prospective case-control study was performed from August 18, 2022 to December 30, 2022. This was a cross-sectional study including 50 women who applied to the gynecology service of Malatya Turgut Özal Training and Research Hospital with complaints of AUB and 50 women without AUB who underwent gynecological examination. The presence of AUB in patients was determined based on clinical examination conducted by a gynecologist and medical records. Demographic and clinical characteristics were recorded. Serum ELA levels were determined by commercial ELISA kit. Results: Serum ELA levels was significantly lower in patients with AUB (581.54±272.25 pg/mL) compared to the healthy group (744.55±300.31 pg/mL, p=0.005). In this study, ELA in patients with AUB showed 98% sensitivity and 80% specificity with a cut off value of 411.41 pg/mL (area under the curve [AUC], 68.1%; p=0.002). Conclusion: Serum ELA levels in patients with AUB were significantly lower than in healthy women. These results show that ELA is a good predictor of the pathophysiological process of AUB.
  • Küçük Resim
    Öğe
    Effect of Altered Iron Metabolism on Hyperinflammation and Coagulopathy in Patients with Critical COVID-19: A Retrospective Study
    (JAMP, 15.01.2022) Kıran,Tuğba Raika; Otlu, Önder; Erdem, Mehmet; Korkmaz, Kübranur; Ota Günay, Özge; İn, Erdal; Bay Karabulut, Aysun
    Abstract: A novel coronavirus disease 2019 (COVID-19) outbreak has started in Wuhan, China, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The relationship between altered iron homeostasis and hyperinflammation may be hallmarks of COVID-19 disease. We aimed to compare some iron (ferritin and iron), inflammation (C-reactive protein [CRP], hemoglobin, lactate dehydrogenase [LDH], neutrophil) and coagulation (prothrombin time [PT], activated partial thromboplastin time [APTT], D-dimer, platelet) marker results of critical COVID-19 patients with healthy controls results. In this single center retrospective study, 50 critical patients diagnosed with COVID-19 were included, demographic, clinical characteristics, severity of disease and laboratory test results were elicited from electronic medical records and compared to 50 healthy people. A statistically significant increase in CRP, LDH, neutrophil, PT, APTT, D-dimer ferritin levels was observed in critical COVID-19 patients compared with healthy people while a statistically significant decrease was observed in hemoglobin and iron levels. In addition, no statistically significant change in platelet levels was observed. Ferroptosis may be a significant cause of multiple organ failure in critical COVID-19 patients. Ferroptosis inhibitors might have potential to combat ferroptosis in COVID-19. Therefore, larger studies are needed to ferroptosis in COVID-19 in vivo and in vitro.
  • Küçük Resim
    Öğe
    Effect of Altered Iron Metabolism on Hyperinflammation and Coagulopathy in Patients with Critical COVID-19: A Retrospective Study
    (2022) Otlu, Önder; Erdem, Mehmet; Korkmaz, Kübranur; Günay, Özge Ota; İn, Erdal; Kıran, Tuğba Raika; Bay Karabulut, Aysun
    Abstract: A novel coronavirus disease 2019 (COVID-19) outbreak has started in Wuhan, China, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The relationship between altered iron homeostasis and hyperinflammation may be hallmarks of COVID-19 disease. We aimed to compare some iron (ferritin and iron), inflammation (C-reactive protein [CRP], hemoglobin, lactate dehydrogenase [LDH], neutrophil) and coagulation (prothrombin time [PT], activated partial thromboplastin time [APTT], D-dimer, platelet) marker results of critical COVID-19 patients with healthy controls results. In this single center retrospective study, 50 critical patients diagnosed with COVID-19 were included, demographic, clinical characteristics, severity of disease and laboratory test results were elicited from electronic medical records and compared to 50 healthy people. A statistically significant increase in CRP, LDH, neutrophil, PT, APTT, D-dimer ferritin levels was observed in critical COVID-19 patients compared with healthy people while a statistically significant decrease was observed in hemoglobin and iron levels. In addition, no statistically significant change in platelet levels was observed. Ferroptosis may be a significant cause of multiple organ failure in critical COVID-19 patients. Ferroptosis inhibitors might have potential to combat ferroptosis in COVID-19. Therefore, larger studies are needed to ferroptosis in COVID-19 in vivo and in vitro.
  • Küçük Resim Yok
    Öğe
    Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome
    (2024) TAŞ, NEVSUN PIHTILI; Baykara, Rabia Aydogan; KAMANLI, Ayhan; Gürbüz, Ali; CÜRE, Erkan; cure, medine cumhur; Erdem, Mehmet
    Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS). Patients and methods: The retrospective study was conducted between May 2022 and February 2023. Fifty-eight female FS patients (mean age: 45.2±9.9 years; range, 25 to 66 years) and 30 age- and body mass index-matched control subjects (mean age: 43.1±9.9 years; range, 26 to 67 years) were included in the study. Apelin and PCSK9 levels of all individuals were measured using appropriate methods. Results: The levels of PCSK9 (173.2±62.2 vs. 75.1±44.1, p<0.001) and apelin (354.6±195.5 vs. 229.0±83.2, p<0.001) were significantly higher in patients with FS compared to the control group. A positive correlation was found between PCSK9 and apelin levels and various measures, including the Fibromyalgia Impact Questionnaire (FIQ), Symptom Severity Scale (SSS), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). Additionally, there was a positive correlation between apelin levels and FIQ, SSS, PSQI, Beck Anxiety Inventory, and BDI scores. The optimal cutoff value for PCSK9 in predicting FS was 110.0 ng/mL, with a sensitivity of 84.5% and specificity of 83.9% (area under the curve [AUC]=0.920, 95% confidence interval [CI]: 0.852-0.987, p<0.001). For apelin, the optimal cutoff value for predicting FS was 258.8 ng/L, with a sensitivity of 63.8% and specificity of 64.5% (AUC=0.732, 95% CI: 0.623–0.840, p<0.001). Conclusion: Our findings suggest that PCSK9 may play a role in FS etiology and potentially contribute to oxidative stress. Increased apelin levels may be a compensatory response to high oxidative stress, possibly leading to hyperalgesia. Both PCSK9 and apelin can be predictive markers for FS.